Interventional Glaucoma

AMDX-2011P aims to revolutionize glaucoma detection with micron-level amyloid beta tracking.

Ab-interno implantation of a supraciliary allograft bio-tissue successfully reduced intraocular pressure (IOP) with comparable safety to other minimally invasive glaucoma surgical (MIGS) procedures

Eight patients were able to receive a second implant at 21 weeks, with no product related adverse effects.

More testing is needed to ensure accuracy across different groups

According to the company, its Phase I/II trial is being initiated to investigate SpyGlass platform for the long-term delivery of bimatoprost in patients with glaucoma and visually significant cataracts.

According to the company, its ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver the world's first femtosecond laser image-guided high-precision trabeculotomy.

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.

Results showed that the PAUL Glaucoma Implant is an effective glaucoma drainage device that provides effective IOP lowering, similar to that achieved with the Baerveldt Glaucoma Implant, but with lower rates of complications

The approach to lowering intraocular pressure reduces medication burden without risking graft rejection

Glaucoma specialist Joel Solano, MD, connects patients diagnosed with glaucoma with digital health solutions that can help prevent blindness and vision loss.

Preservative-free Iyuzeh, launched more than 10 years ago, currently is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly, according to the company.

Highlighting the benefits of Iridex's updated P3 Probe and Cyclo G6® Laser software for MicroPulse® transscleral laser therapy. The redesigned probe improves ergonomics and visibility, while the user-friendly software ensures precise, reproducible glaucoma treatments.

Peter J. McDonnell, MD, and Neda Shamie, MD, discuss the transformative impact of minimally invasive glaucoma surgery (MIGS) on glaucoma care and its integration with cataract surgery, sharing insights and practical tips for ophthalmologists.

As a gold medalist with profound vision loss, she will lead advocacy efforts for people with glaucoma that are designed to empower patients to participate actively in their glaucoma treatment journey

In the years to come, Ciliatech will release more data around their novel Cilioscleral Interposition Device (CID)

The director of Frankfurt’s Bürgerhospital eye hospital shared 7 years’ data on the iStent inject®

Leaders must confront issues perpetuating unequal access, unfair practices.

The glaucoma specialist spoke about his ESCRS agenda–and his calendar for 2024

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

Patients with HTG had significantly fewer mtDNA copies per nuclear DNA.

As part of the meeting’s MIGS programme, Keith Barton, MD, FRCP, FRCS, FRCOphth, shared data from the iTrack™ Global Data Registry

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.